Watson Confirms LUMIGAN(R) and LATISSE(R) Patent Challenges

_{//health-fitness.news-articles.net/content/2012/ .. s-lumigan-r-and-latisse-r-patent-challenges.html}
^{Published in Health and Fitness on Tuesday, April 3rd 2012 at 6:26 GMT by Market Wire}  

Watson Confirms LUMIGAN(R) and LATISSE(R) Patent Challenges -- PARSIPPANY, N.J., April 3, 2012 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about WPI

- Paragraph IV Litigations Underway -

PARSIPPANY, N.J., April 3, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: [ WPI ]) today confirmed that its subsidiary, Watson Laboratories, Inc., filed Abbreviated New Drug Applications (ANDAs) with the U.S. Food and Drug Administration (FDA) seeking approval to market Bimatoprost Ophthalmic Solution, 0.01% and Bimatoprost Ophthalmic Solution, 0.03%. Watson's ANDA products are generic versions of Allergan, Inc.'s LUMIGAN® 0.01% and LATISSE® products, respectively. LUMIGAN® 0.01% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension. LATISSE® is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness and darkness.

Allergan, Inc. filed suit against Watson in the United States District Court for the Eastern District of Texas on March 23, 2012 seeking to prevent Watson from commercializing its generic version of LUMIGAN® 0.01% prior to the expiration of certain U.S. patents.  Allergan, Inc. and Duke University filed suit against Watson in the United States District Court for the Middle District of North Carolina on March 30, 2012 seeking to prevent Watson from commercializing its generic version of LATISSE® prior to the expiration of certain U.S. patents. Each lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in separate stays of final FDA approval of Watson's ANDAs.  Each stay will be in effect for up to 30 months from the date the plaintiffs received notice of Watson's ANDA filing or until final resolution of the litigation, subject to any other exclusivities.

For the twelve months ending January 31, 2012, LUMIGAN® and LATISSE® had total U.S. sales of approximately $409 million and $80 million, respectively, according to IMS Health data.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at [ http://www.watson.com ].

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

LUMIGAN® and LATISSE® are registered trademarks of Allergan, Inc.

SOURCE Watson Pharmaceuticals, Inc.

RELATED LINKS
[ http://www.watson.com ]